First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Res...
January 04 2017 - 11:45AM
Marketwired
First-In-Human Assessment of LB-100, Lixte Biotechnology's
Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer
Research
EAST SETAUKET, NY-(Marketwired - Jan 4, 2017) - Lixte
Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the
publication online of Phase 1 results of its novel anti-cancer
compound in Clinical Cancer Research, entitled "Safety,
tolerability, and preliminary activity of LB-100, an inhibitor of
protein phosphatase 2A, in patients with relapsed solid tumors."
(https://doi.org/10.1158/1078-0432.CCR-16-2299)
John S. Kovach, M.D., Founder and President of Lixte said "We
are encouraged that ten (46.7%) of twenty-one patients receiving at
least 2 cycles of LB-100, a small molecule inhibitor of protein
phosphatase (PP2A), achieved stable disease without limiting
toxicity for up to 15 cycles of therapy including one patient with
pancreatic cancer who had a partial regression. PP2A has long been
recognized as a potentially important cancer treatment target but
its inhibition was thought to be too toxic for clinical use. This
Phase 1 study demonstrates the safety and tolerability of PP2A
inhibition in patients with refractory solid tumors."
Dr. Kovach continued "In numerous animal models of cancer,
inhibition of PP2A by LB-100 enhanced the anti-tumor activity of
standard chemotherapy drugs and radiation without significantly
enhancing their toxicity by altering cell cycle regulation and the
DNA-damage repair response pathways. The mechanism by which LB-100
used alone apparently inhibited the growth of a variety of
cancers in patients in the recently completed Phase I trial is not
clear but PP2A activity is reduced by mutation directly or
indirectly in many cancer types rendering them vulnerable to
pharmacologic inhibition of PP2A. The results reported in
Clinical Cancer Research support further development of
LB-100 alone and in combination with standard cytotoxic regimens
for a broad spectrum of tumors."
About Lixte Biotechnology Holdings, Inc. Lixte is a drug
discovery company that uses biomarker technology to identify enzyme
targets associated with serious common diseases and then design
novel compounds to attack those targets. Lixte's product pipeline
encompasses two major categories of compounds at various stages of
pre-clinical and clinical development that the Company believes
have broad therapeutic potential not only for cancer but also for
other debilitating and life-threatening diseases.
Forward-Looking Statements This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at
www.lixte.com.
Eric J. Forman, Esq. 646-894-3135 eforman@lixte.com